Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate Cancer

Bryan A. Mehlhaff, MD
Published Online: Tuesday, Jan 10, 2017



Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Approximately 8 years ago, Mehlhaff says, urologists used to administer hormone therapy to these patients, as well as first generation receptor blockers, and overall, there were not many efficacious treatment options.

Now, though, oncologists have managed to literally double the life expectancy of patients with metastatic castration-resistant prostate cancer. Moreover, Mehlhaff explains, those are quality added years, not just life extension. He says he often tells his patients that, while it may not be ideal to be diagnosed with this disease, the plethora of treatment options now available hold promise for their future health.

Mehlhaff also emphasizes the notion that every urologist is capable of understanding how to treat patients with advanced prostate cancer. As the landscape evolves, urologists must adapt to these new ways of thinking about the disease as a continuing, hormone-sensitive cancer.



Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Approximately 8 years ago, Mehlhaff says, urologists used to administer hormone therapy to these patients, as well as first generation receptor blockers, and overall, there were not many efficacious treatment options.

Now, though, oncologists have managed to literally double the life expectancy of patients with metastatic castration-resistant prostate cancer. Moreover, Mehlhaff explains, those are quality added years, not just life extension. He says he often tells his patients that, while it may not be ideal to be diagnosed with this disease, the plethora of treatment options now available hold promise for their future health.

Mehlhaff also emphasizes the notion that every urologist is capable of understanding how to treat patients with advanced prostate cancer. As the landscape evolves, urologists must adapt to these new ways of thinking about the disease as a continuing, hormone-sensitive cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary MalignanciesMay 27, 20171.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Publication Bottom Border
Border Publication